Expensify FY 2025 results set the stage for a margin story investors will be watching closely

Expensify (EXFY) has laid out a challenging FY 2025 finish, with Q4 revenue of about US$35.2 million alongside a basic EPS loss of US$0.08 and net income excluding extra items showing a loss of US$7.1 million. Over recent periods the company has seen quarterly revenue move from US$37.0 million in Q4 FY 2024 to the US$35 million to US$36 million range across FY 2025. Basic EPS has stayed in loss making territory between roughly US$0.02 and US$0.10 per share. With the stock price around US$0.95 and trailing 12 month losses, the latest print keeps the focus squarely on whether management can eventually lift margins and stem earnings pressure.

With the headline figures on the table, the next step is to set these results against the prevailing narratives around Expensify to see which stories the numbers back up and which they start to challenge.

Losses widen to US$7.1 million despite steady revenue

• Q4 FY 2025 revenue came in at US$35.2 million, roughly in line with the US$35 million to US$36 million range seen through the year, while net income excluding extra items moved from a US$1.3 million loss in Q4 FY 2024 to a US$7.1 million loss in Q4 FY 2025.
• Bulls argue that Expensify's AI powered platform and global expansion can eventually improve margins, but the trailing 12 month loss of US$21.4 million and five year loss growth rate of about 13.3% a year are a clear test of that view.
  • Supporters point to the bullish case that margins might move from about a 10.7% loss to a small 1.2% profit margin over the next few years. However, current quarterly EPS losses between roughly US$0.02 and US$0.10 per share underline how far the company is from that scenario.
  • The bullish narrative also leans on potential revenue growth of 3.6% a year. The provided forecasts instead indicate revenue is expected to decline by about 1.4% a year, which makes the margin story even more important to watch.

Strong believers in the bullish case are effectively betting that today's US$21.4 million trailing loss is the base from which AI and international growth eventually flip the story into positive earnings, so it is worth reading how they connect those dots in the detailed bull case. 🐂 Expensify Bull Case

Trailing losses vs cheap 0.6x P/S multiple

• Over the last 12 months, Expensify generated US$142.1 million in revenue and a basic EPS loss of US$0.23, yet the shares trade on a P/S of about 0.6x compared with 3.5x for the US software industry and 1.3x for peers.
• Consensus narrative highlights that the stock looks inexpensive on simple sales multiples, but the fact that analysts do not expect profitability within three years keeps the focus on whether that low P/S reflects risk around future cash flows.
  • Analysts in the balanced view expect revenue to grow by about 1.2% a year and for earnings to reach roughly US$19.6 million by 2028 if margins eventually resemble the wider US software sector, which currently sits around a 13.1% profit margin in the scenario described.
  • Against a current share price of about US$0.95, the only allowed analyst target in this setup is US$1.67. Any gap between that level and the DCF fair value of about US$2.21 reminds you that different models can produce very different views of what "cheap" means for an unprofitable business.

US$0.95 share price vs DCF fair value of US$2.21

• The shares trade around US$0.95 while the supplied DCF fair value is US$2.21, implying the market price sits well below that model based estimate despite trailing 12 month losses and forecasts that do not show a return to profitability within three years.
• Bears focus on the risk that higher brand spend and product investment may not translate into earnings, and the earnings track record here gives that argument some support.
  • Across FY 2025, net income excluding extra items stayed in loss territory every quarter between roughly US$2.3 million and US$8.8 million, which lines up with the cautious view that heavier marketing and technology spending has yet to show up in improved EPS.
  • Bearish analysts also point to forecast revenue declines of about 0.8% a year and an expectation that profitability does not arrive in the next three years, so the current discount to DCF fair value is being weighed against the risk that those losses may continue.

If you are weighing whether the current US$0.95 price reflects the cautious case or something closer to the DCF fair value of US$2.21, it is worth seeing how skeptics frame the risks around margins and competition in their full bear case. 🐻 Expensify Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Expensify on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of margin hopes and ongoing losses leaves you on the fence, it is worth checking the full picture for yourself and weighing both sides quickly, including 3 key rewards and 1 important warning sign.

Explore Alternatives

Expensify is still reporting consistent revenue alongside ongoing losses, with no clear path to near term profitability, and a low P/S that reflects meaningful risk.

If that mix of steady sales and continued earnings pressure feels uncomfortable, you might want to look at 76 resilient stocks with low risk scores to focus on companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.